1. Home
  2. Companies
  3. MAP
  4. Material Events

Microba Life Sciences (ASX:MAP) — Material Events

ASX:MAP · 12 articles in the last 12 months · 100% assessed

Click a band to jump to that tier

Significant 10 articles Notable 2 articles Not Assessed 0 articles
Major ≥90 Significant 75–89 Notable 50–74 Routine <50 Not assessed
Significant Score 75–89
10
Microba Surges 145% in Test Volumes, Eyes FY26 Break-EvenMedium
Microba reports 145% test volume growth, on track for FY26 break-even with $14.5M capital raise
28 Oct 2025 ·Quarterly Activities Report & Appendix 4C ·85
Microba Drives Record Test Sales and Clinical Adoption Amid Strategic ShiftMedium
Microba reports record Q4 test sales, 30% FY25 revenue growth, and $14.5m capital raise
22 July 2025 ·Quarterly Activities Report & Appendix 4C ·85
Microba Advances Diagnostics with 30% Revenue Growth and UK ExpansionHigh
Microba reports 30% revenue growth, narrows FY25 loss, strengthens cash with $14.5M raise, advances core diagnostics and UK expansion
26 Aug 2025 ·Annual Report ·85
Microba Accelerates Growth with New Features and Eyes US Market BreakthroughMedium
Microba reports strong Q1 FY26 growth, new product features, and upcoming therapeutic deal catalysts
28 Oct 2025 ·Quarterly Investor Presentation ·85
Microba Raises $5 Million to Accelerate Diagnostics Growth and Target Break-Even by 2027Medium
Microba raises $5 million to fund growth and achieve cashflow break-even by 2027
12 June 2026 ·Capital Raising ·85
Microba Doubles Core Testing Revenue as UK and Clinic Contracts Drive GrowthMedium
Microba Q3 FY26 core testing revenue doubles; new clinic contracts and UK growth drive momentum
30 Apr 2026 ·Quarterly Activities Report & Appendix 4C ·85
Microba Accelerates Core Test Growth with 90% Volume Surge and $2.1M RevenueMedium
Microba reports 90% core test volume growth, $2.1M core revenue, cost savings, and strong clinical adoption
29 Jan 2026 ·Quarterly Activities Report & Appendix 4C ·85
Microba Accelerates Growth, Eyes Break-Even with $15.7m Revenue in Q2 FY26Medium
Microba reports strong Q2 FY26 growth, targets regional break-even, advances therapeutics pipeline
29 Jan 2026 ·Quarterly Investor Presentation ·85
Microba Accelerates Growth with Record Q4 Sales and Eyes FY26 Break-EvenMedium
Microba reports strong Q4 FY25 growth, advances diagnostics and therapeutics pipeline, targets FY26 break-even
22 July 2025 ·Quarterly Investor Presentation ·85
Microba Life Sciences Seeks $6 Million Capital Boost with SPP and Placement Pending Shareholder NodMedium
Microba Life Sciences launches $6 million capital raise via SPP and Placement with shareholder approval pending
19 June 2026 ·Prospectus ·75
Not Assessed Low Score, or missing data
0

No articles in this tier for the last 12 months.